World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
116
Citations
68907
World Ranking
4277
National Ranking
2338

Overview

Eugene R. Schiff is affiliated with the University of Miami in the United States. Their research work primarily focuses on Medicine, with specific expertise in Epidemiology, Hepatology, and Infectious Diseases. They have also contributed to studies in Endocrinology, Diabetes and Metabolism, as well as Cardiology and Cardiovascular Medicine.

The main topics covered in Eugene R. Schiff's publications include:

  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • Hepatitis Viruses Studies and Epidemiology
  • Diet, Metabolism, and Disease
  • Lipid metabolism and disorders
  • Liver Disease and Transplantation

They have published extensively in the following venues:

  • Journal of Hepatology (6 publications)
  • Hepatology (1 publication)
  • Journal of Viral Hepatitis (1 publication)
  • Liver Transplantation (1 publication)
  • JHEP Reports (1 publication)

Notable recent papers authored or coauthored by Eugene R. Schiff include:

  • "Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial" (2021, Hepatology)
  • "The case for simplifying and using absolute targets for viral hepatitis elimination goals" (2020, Journal of Viral Hepatitis)
  • "Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection" (2022, Journal of Hepatology)
  • "Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection" (2022, Journal of Hepatology)
  • "Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study" (2020, Journal of Hepatology)

Frequently collaborating coauthors include:

  • Paul Y. Kwo (8 publications)
  • Mark Sulkowski (7 publications)
  • Ronald Nahass (7 publications)
  • Edward Gane (7 publications)
  • Ira M. Jacobson (7 publications)

Best Publications

  • Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

    John G. Mchutchison;Stuart C. Gordon;Eugene R. Schiff;Mitchell L. Shiffman

  • Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

    George Ostapowicz;Robert J. Fontana;Frank V. Schioødt;Anne Larson

  • Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

    Arie Regev;Mariana Berho;Lennox J. Jeffers;Clara Milikowski

  • Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

    Davis Gl;Balart La;Schiff Er;Lindsay K

  • Lamivudine as initial treatment for chronic hepatitis B in the United States.

    Jules L. Dienstag;Eugene R. Schiff;Teresa L. Wright;Robert P. Perrillo

  • Diseases of the liver

    Leon Schiff;Eugene R. Schiff

  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

    John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  • Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

    Nezam Afdhal;K. Rajender Reddy;David R. Nelson;Eric Lawitz

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

    Ting Tsung Chang;Yun Fan Liaw;Shun Sheng Wu;Eugene Schiff

  • A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection

    Jules L. Dienstag;Robert P. Perrillo;Eugene R. Schiff;Maria Bartholomew

  • Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

    Anna S.F. Lok;Ching Lung Lai;Nancy Leung;Guang Bi Yao

  • A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

    Robert P. Perrillo;Eugene R. Schiff;Gary L. Davis;Henry C. Bodenheimer

  • Histological outcome during long-term lamivudine therapy.

    Jules L. Dienstag;Robert D. Goldin;E.Jenny Heathcote;H.W.L. Hann

  • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

    Paul Y Kwo;Eric J Lawitz;Jonathan McCone;Eugene R Schiff

  • A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

    Karen L. Lindsay;Christian Trepo;Tobias Heintges;Mitchell L. Shiffman

  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

    Michael Charlton;Gregory T. Everson;Steven L. Flamm;Princy Kumar

  • Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B

    Ching Lung Lai;Jules Dienstag;Eugene Schiff;Nancy W.Y. Leung

  • National Institutes of Health Consensus Development Conference panel statement: Management of hepatitis C

    D. W. Powell;B. Z. Abramson;J. A. Balint;S. Belle

Frequent Co-Authors

Andreas G. Tzakis
Andreas G. Tzakis Cleveland Clinic
K. Rajender Reddy
K. Rajender Reddy University of Pennsylvania
Ira M. Jacobson
Ira M. Jacobson New York University
Mitchell L. Shiffman
Mitchell L. Shiffman Bon Secours Health System
Jules L. Dienstag
Jules L. Dienstag Harvard University
Joshua Miller
Joshua Miller Northwestern University
William M. Lee
William M. Lee The University of Texas Southwestern Medical Center
Paul Martin
Paul Martin University of Miami
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Eric Lawitz
Eric Lawitz The University of Texas at Austin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens doors to various related fields and flexible study options. Many students seek alternatives to traditional, in-person programs, especially if they need to balance work with education. Fortunately, online degrees and bridge programs can offer accelerated and convenient pathways for career advancement.

Nursing is a popular starting point, with many schools now providing lpn to rn programs without teas test requirements—making it easier for licensed practical nurses to advance. For those who want to move into leadership roles, enrolling in a healthcare administration degree online accredited can prepare you for management positions without sacrificing flexibility.

Registered nurses can further specialize through rn to np programs, which provide a bridge to advanced practice and nurse practitioner roles. Meanwhile, those interested in preventive care and wellness may consider online nutrition degree programs that can lead to careers in clinical nutrition, public health, or education.

These online options offer flexibility, career growth, and access to high-demand healthcare roles—making them valuable pathways for anyone committed to the medical field.

Best Scientists Citing Eugene R. Schiff

Trending Scientists

Recently Published Articles